These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 15958617

  • 1. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs.
    Vikhanskaya F, Siddique MM, Kei Lee M, Broggini M, Sabapathy K.
    Clin Cancer Res; 2005 Jun 15; 11(12):4348-56. PubMed ID: 15958617
    [Abstract] [Full Text] [Related]

  • 2. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.
    Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T.
    Cancer Cell; 2003 Apr 15; 3(4):387-402. PubMed ID: 12726864
    [Abstract] [Full Text] [Related]

  • 3. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism.
    Siddique M, Sabapathy K.
    Oncogene; 2006 Jun 15; 25(25):3489-500. PubMed ID: 16462765
    [Abstract] [Full Text] [Related]

  • 4. Effects of p73 gene overexpression on apoptosis and chemosensitivity of human lung adenocarcinoma cell line A549.
    He Y, Fan SZ, Jiang YG.
    Ai Zheng; 2006 Aug 15; 25(8):925-32. PubMed ID: 16965670
    [Abstract] [Full Text] [Related]

  • 5. The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.
    Cattelani S, Ferrari-Amorotti G, Galavotti S, Defferrari R, Tanno B, Cialfi S, Vergalli J, Fragliasso V, Guerzoni C, Manzotti G, Soliera AR, Menin C, Bertorelle R, McDowell HP, Inserra A, Belli ML, Varesio L, Tweddle D, Tonini GP, Altavista P, Dominici C, Raschellà G, Calabretta B.
    Neoplasia; 2012 Jul 15; 14(7):634-43. PubMed ID: 22904680
    [Abstract] [Full Text] [Related]

  • 6. The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse models.
    Phang BH, Sabapathy K.
    Oncogene; 2007 May 10; 26(21):2964-74. PubMed ID: 17130838
    [Abstract] [Full Text] [Related]

  • 7. A naturally occurring p73 mutation in a p73-p53 double-mutant lung cancer cell line encodes p73 alpha protein with a dominant-negative function.
    Huqun, Endo Y, Xin H, Takahashi M, Nukiwa T, Hagiwara K.
    Cancer Sci; 2003 Aug 10; 94(8):718-24. PubMed ID: 12901798
    [Abstract] [Full Text] [Related]

  • 8. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
    Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R.
    Clin Cancer Res; 2005 Dec 01; 11(23):8372-83. PubMed ID: 16322298
    [Abstract] [Full Text] [Related]

  • 9. CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.
    Andrade Filho PA, Ito D, Deleo AB, Ferris RL.
    Cancer Immunol Immunother; 2010 Oct 01; 59(10):1561-8. PubMed ID: 20577877
    [Abstract] [Full Text] [Related]

  • 10. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
    Vikhanskaya F, D'Incalci M, Broggini M.
    Nucleic Acids Res; 2000 Jan 15; 28(2):513-9. PubMed ID: 10606650
    [Abstract] [Full Text] [Related]

  • 11. c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-beta-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells.
    Thottassery JV, Westbrook L, Someya H, Parker WB.
    Mol Cancer Ther; 2006 Feb 15; 5(2):400-10. PubMed ID: 16505115
    [Abstract] [Full Text] [Related]

  • 12. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo.
    Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T.
    Oncogene; 2004 Apr 22; 23(19):3328-37. PubMed ID: 15077186
    [Abstract] [Full Text] [Related]

  • 13. Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells.
    Liu J, Uematsu H, Tsuchida N, Ikeda MA.
    Mol Cancer; 2011 Jul 31; 10():95. PubMed ID: 21801448
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
    d'Amato TA, Landreneau RJ, Ricketts W, Huang W, Parker R, Mechetner E, Yu IR, Luketich JD.
    J Thorac Cardiovasc Surg; 2007 Feb 31; 133(2):352-63. PubMed ID: 17258563
    [Abstract] [Full Text] [Related]

  • 15. Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein.
    Ozeki C, Sawai Y, Shibata T, Kohno T, Okamoto K, Yokota J, Tashiro F, Tanuma S, Sakai R, Kawase T, Kitabayashi I, Taya Y, Ohki R.
    J Biol Chem; 2011 May 20; 286(20):18251-60. PubMed ID: 21454683
    [Abstract] [Full Text] [Related]

  • 16. Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas.
    Loeb KR, Asgari MM, Hawes SE, Feng Q, Stern JE, Jiang M, Argenyi ZB, de Villiers EM, Kiviat NB.
    PLoS One; 2012 May 20; 7(4):e34422. PubMed ID: 22545084
    [Abstract] [Full Text] [Related]

  • 17. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.
    Di Como CJ, Gaiddon C, Prives C.
    Mol Cell Biol; 1999 Feb 20; 19(2):1438-49. PubMed ID: 9891077
    [Abstract] [Full Text] [Related]

  • 18. p73 and MDM2 confer the resistance of epidermoid carcinoma to cisplatin by blocking p53.
    Hayashi S, Ozaki T, Yoshida K, Hosoda M, Todo S, Akiyama S, Nakagawara A.
    Biochem Biophys Res Commun; 2006 Aug 18; 347(1):60-6. PubMed ID: 16815295
    [Abstract] [Full Text] [Related]

  • 19. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer.
    McGregor JM, Harwood CA, Brooks L, Fisher SA, Kelly DA, O'nions J, Young AR, Surentheran T, Breuer J, Millard TP, Lewis CM, Leigh IM, Storey A, Crook T.
    J Invest Dermatol; 2002 Jul 18; 119(1):84-90. PubMed ID: 12164929
    [Abstract] [Full Text] [Related]

  • 20. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T, Wang J, Chen X, Meng X, Song X, Lu Z, Jiang H, Liu L.
    Tumour Biol; 2010 Aug 18; 31(4):287-95. PubMed ID: 20422343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.